All News

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), named public health expert and former commissioner of the Food and Drug Administration (FDA) Scott Gottlieb, M.D., as the keynote speaker for the 37th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow.®

The phase 3 IMvigor130 study is the first to assess a cancer immunotherapy combination in previously untreated advanced bladder cancer.

High school students will explore pharmacy careers through activities such as extracting DNA from strawberries, and getting out of a pharmacy-themed escape room, during the upcoming Discover Pharmacy day camp, at Wilkes University.

By searching for hyperactive cell signals in primary effusion lymphoma, researchers were able to find a pathway that can be blocked to limit tumor growth.

Top news of the day from across the health care landscape.

Vizient, Inc. has released its July 2019 Drug Price Forecast, which projects that health systems can expect a 4.57% increase for pharmaceutical purchases made in 2020.

Pharmacy and public health associations have released statements following the recent shootings in California, Texas, and Ohio, and some are discussing what actions they can take to prevent further gun-related injury and death.

Drug overdoses involving opioids have increased, and naloxone can be a life-saving drug to prevent deaths.

A study in the Bukoba municipality of Tanzania has suggested that scaling up HIV testing, improving linkages to HIV care, and strengthening retention of antiretroviral therapy interventions can help increase viral load suppression (VLS).

A regimen of afatinib as a first-line treatment followed by osimertinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer was found to significantly improve overall survival.

Identifying gene-pair relationships may help scientists understand why mutations in certain genes lead to cancer in certain tissues.

Top news of the day from across the health care landscape.

Officials with the FDA issued a statement to clarify data accuracy issues with recently-approved gene therapy Zolgensma (onasemnogene abeparvovec-xioi, AveXis), a product intended to treat spinal muscular atrophy (SMA) in children under 2 years old.

Officials with the FDA are assessing data accuracy issues related to Zolgensma, but have no major concerns about the spinal muscular atrophy treatment remaining on the market.

An analysis of previous studies of children and young adults with ADHD has quantified the extent to which stimulant treatment reduces the development of mood disorders, problems in school, conduct disorders, substance use disorders, and other problems.

The opioid epidemic has become widespread throughout the country, and it is considered a top public health priority.

Effective patient-provider communication is critical to the healing process and it begins the moment the patient makes contact with the staff and continues even after the patient fills his prescription at the pharmacy.

Research could lead to the development of new cancer treatments to stop tumor growth.

Top news of the day from across the health care landscape.

Permethrin, an insecticide of the pyrethroid family, is used against mites, ticks, and other insects.

Over the last 5 years, more than 4000 FDA-regulated clinical trials were initiated worldwide for rare disease treatments.

A patient presents with dizziness and is looking for ear wax treatment, but the cause is much more serious than expected.

Pexidartinib (Turalio, Daiichi Sankyo) is indicated for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Top news of the day from across the health care landscape.

Researchers find anticholinergic drugs may cause vascular dementia.

The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigourous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.